Neurocrine Biosciences (NBIX) Tops Q2 EPS by 69c, Revenues Beat
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Neurocrine Bio. (NBIX) PT Raised to $145 at Piper Sandler Due to Ingrezza Long-Term Potential
August 4, 2020 9:10 AM EDTPiper Sandler analyst David Amsellem raised the price target on Neurocrine Bio. (NASDAQ: NBIX) to $145.00 (from $141.00) while maintaining an Overweight rating, citing Ingrezza sales and volumes, a cinrecerfront Phase III study in CAH patients, an increasingly deep pipeline, and the low rates of TD... More
